News

Australia's TGA Denies Lecanemab Registration by BioArctic

Australia's TGA Denies Lecanemab Registration by BioArctic

BioArctic's Lecanemab Non-Approval by Australia's TGA

BioArctic AB's (publ) (NASDAQ: BIOA) partner Eisai has announced that Australia's Therapeutic Goods Administration (TGA) has opted not to approve lecanemab for the treatment of early Alzheimer's disease (AD). This is a significant blow for both patients and healthcare professionals eager for effective Alzheimer's treatments.

Despite the disappointment, Eisai remains determined to find pathways for Australians to access lecanemab. The company is considering various approaches, including a potential review by the Administrative Review Tribunal to reassess the TGA's decision.

The Decision-Making Process of the TGA

Initially, in October 2024, the TGA decided against registering lecanemab. When Eisai sought a review of this decision in December 2024, they presented an indication aligned with the approvals from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA).

During the review, the TGA decided on a narrower indication, proposing approval only for patients who are ApoE4 noncarriers, leaving many potential patients without options. Eisai's appeal for a broader indication that includes heterozygotes was also turned down.

Eisai's Efforts and The Impact on Patients

Gunilla Osswald, CEO at BioArctic, expressed deep disappointment regarding the TGA's decision. She voiced concern for the patients and families who will face longer waits for a treatment that could effectively alter the progression of a disease that deeply affects their quality of life.

In Australia, the number of individuals living with dementia is projected to rise significantly, from approximately 411,000 in 2023 to around 849,000 by 2058. Given that Alzheimer's disease is the leading cause of dementia, accounting for 60-70% of cases, the urgency for effective treatment options is paramount.

Understanding Alzheimer's Disease

Alzheimer's is a complex condition characterized by amyloid-beta (A?) aggregation in the brain, which can occur 15 to 20 years prior to the manifestation of symptoms. This disease progresses over time, creating a myriad of challenges for patients and their families. The need for innovative treatments that can slow down the disease's progress is evident.

Lecanemab provides a novel approach to combat AD. Its mechanism works in two significant ways: it clears protofibrils, which are the most toxic form of A?, and it rapidly reduces plaque in the brain. This dual action contributes to the reduction of both cognitive and functional decline in patients.

Global Approval Status of Lecanemab

Notably, lecanemab has already received approvals in 11 markets worldwide, including the U.S., Japan, China, and the United Kingdom. Regulatory applications are pending in the EU and several additional countries. In February 2025, lecanemab received a reaffirmation of its positive opinion from the EU's Committee for Medicinal Products for Human Use, which had previously expressed favorable views.

Collaboration and Future Steps

The development of lecanemab stems from a longstanding partnership between BioArctic and Eisai. The antibody was initially developed by BioArctic, with a focus on countering the effects of Alzheimer's based on groundbreaking research. Eisai manages clinical development and market applications while also preparing for joint commercialization with BioArctic in the Nordic region.

BioArctic boasts a rich portfolio targeting neurodegenerative diseases, working tirelessly to bring new treatments to market. Their collaborative endeavors, particularly around lecanemab, reflect a commitment to addressing the needs of those suffering from Alzheimer's.

Frequently Asked Questions

What was the TGA's decision regarding lecanemab?

The Therapeutic Goods Administration decided not to approve lecanemab for treating early Alzheimer's disease, impacting availability for patients in Australia.

Why did Eisai appeal the TGA's decision?

Eisai sought to have the TGA reconsider its decision in hopes of allowing more patients to access lecanemab, particularly those who might benefit from its use.

What are the future plans for lecanemab?

BioArctic and Eisai are exploring options to appeal the TGA's decision and continue working on global approvals, with lecanemab being available in multiple markets.

How does lecanemab work?

Lecanemab functions by clearing toxic protofibrils and reducing plaque, aiming to decrease cognitive decline in early Alzheimer’s patients.

What is the significance of this denial for Alzheimer's patients?

This decision prolongs the wait for effective treatment options for patients, highlighting a pressing need for innovative solutions in Alzheimer’s care.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

StoneX Selloff Puts Earnings Quality Under a Harsh Lens

Updated Category News Views 120

A revenue beat can turn downright useless when the profit line springs a leak. StoneX Group delivered operating revenue above expectations and record full-year results, then watched investors hammer the stock after fiscal fourth-quarter diluted earnings per share landed at $0.66. That was $0.15 below the roughly $0.81 consensus cited in the notice, and other estimates...

Continue Reading
Korla Kiln Gains Show How Cement Efficiency Is Won

Updated Category News Views 79

A cement kiln does not care about corporate slogans; it cares whether the flame holds, the bearings stay alive, and the feed keeps moving. That is why the work at Xinjiang Tianshan Cement's Tashidian branch in Korla deserves a closer look. This is not a glossy tale about a futuristic factory appearing overnight. It is an account of an old, unforgiving industrial process...

Continue Reading
Zensar’s AI Forum Puts Operations Before the AI Hype

Updated Category News Views 111

Johannesburg’s AI conversation seems to be shedding its costume jewelry at last. Zensar’s invitation-only CIS Converge 2026 forum, held on November 20, put the attention where it belongs: not on breathless demos, but on whether companies can turn AI into sturdier operations, better customer experiences, and something resembling a measurable return. That is a healthier...

Continue Reading
Shenzhen’s 50-Year Message Carries Real Trade Weight

Updated Category News Views 68

A city once framed as a frontier fishing village is being presented as China’s sharpest recent economic before-and-after picture. At the welcome dinner for the 33rd APEC Economic Leaders’ Meeting in Shenzhen, President Xi Jinping gave guests a compact geographic guide to China’s past: Xi’an for thousands of years, Beijing for 500 years, Shanghai for 100 years, and...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 73

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
Central Florida Buyers Face the Cash Reality First

Updated Category News Views 94

A house hunt can go sideways before the first showing if the buyer has confused a dream budget with a real one. Tom McKnight’s guidance for first-time buyers in Central Florida lands on the unglamorous stuff, which is exactly where it ought to land: cash, credit, financing, insurance, taxes, and the physical condition of the house. Nobody enjoys staring at lender...

Continue Reading
Mimic Bets Virtual Patching Can Calm AI Patch Chaos

Updated Category News Views 100

Three ugly outages in four days can make even hardened technology buyers reconsider the sacred ritual of “patch immediately.” Mimic’s new Virtual Patching offering arrives squarely in that uncomfortable gap: a vulnerability is known, attackers may be moving fast, and the proper vendor update still needs testing before somebody detonates production. The company’s...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 31

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 85

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
SQM Investigation Puts Chile Approval Claims on Trial

Updated Category News Views 71

A Regulatory Promise Meets a Rough Earnings Reaction A 5.52% haircut after disappointing quarterly numbers is the sort of thing that makes shareholders stop pretending every loose management comment is harmless. Sociedad Química y Minera de Chile, NYSE:SQM, is facing an investigation by Levi & Korsinsky into public statements concerning regulatory matters, particularly...

Continue Reading